Evidence map›Paper›PMID 30620686›Full record

ArticleCirculation research2019

Pak2 as a Novel Therapeutic Target for Cardioprotective Endoplasmic Reticulum Stress Response.

Pablo Binder, Shunyao Wang, Maria Radu, Min Zin, Lucy Collins, Saba Khan, Yatong Li, Karolina Sekeres, Neil Humphreys, Eileithyia Swanton and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 82 citations in OpenAlex.

  1. Computational Identification of New Dual PAK4 and NAMPT Inhibitors.International journal of molecular sciences · 2026
    Article
  2. A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 3 countries.

Pablo BinderFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Shunyao WangFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Maria RaduCancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA (M.R., J.C.).
Min ZinFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Lucy CollinsFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Saba KhanFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Yatong LiFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Karolina SekeresInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universitaet Dresden, Germany (K.S., K.G.).
Neil HumphreysFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Eileithyia SwantonFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Adam ReidFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Fay PuEdinburgh University Medical School, United Kingdom (F.P.).
Delvac OceandyFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Kaomei GuanInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universitaet Dresden, Germany (K.S., K.G.).
Susanne S HilleDepartment of Internal Medicine III, University of Kiel, Germany (S.S.H., N.F., O.J.M.).
Norbert FreyDepartment of Internal Medicine III, University of Kiel, Germany (S.S.H., N.F., O.J.M.).
Oliver J MüllerDepartment of Internal Medicine III, University of Kiel, Germany (S.S.H., N.F., O.J.M.).
Elizabeth J CartwrightFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Jonathan ChernoffCancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA (M.R., J.C.).
Xin WangFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
Wei LiuFrom the Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom (P.B., S.W., M.Z., L.C., S.K., Y.L., N.H., E.S., A.R., D.O., E.J.C., X.W., W.L.).
University of Manchester · GBKiel University · DEFox Chase Cancer Center · USUniversity Hospital Carl Gustav Carus · DEUniversity of Edinburgh · GB

Funding

The Role of p21-Activated Kinases in Malignant MesotheliomaR01CA148805 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN, TESTA, JOSEPH R. · 2011 to 2020
$4.0M
Targeting the Kinome in Neurofibromatosis type 1R01CA142928 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 2010 to 2019
$3.9M
British Heart Foundation FS/15/16/31477British Heart Foundation FS/19/39/34447British Heart Foundation PG/12/76/29852British Heart Foundation PG/14/70/31039British Heart Foundation PG/14/71/31063British Heart Foundation PG/16/77/32400British Heart Foundation PG/17/31/32988British Heart Foundation PG/17/78/33304British Heart Foundation PG/19/53/34499NCI NIH HHS R01 CA142928NCI NIH HHS R01 CA148805
6 · The paper itself

Abstract

rationaleSecreted and membrane-bound proteins, which account for 1/3 of all proteins, play critical roles in heart health and disease. The endoplasmic reticulum (ER) is the site for synthesis, folding, and quality control of these proteins. Loss of ER homeostasis and function underlies the pathogenesis of many forms of heart disease.

objectiveTo investigate mechanisms responsible for regulating cardiac ER function, and to explore therapeutic potentials of strengthening ER function to treat heart disease. METHODS AND

resultsScreening a range of signaling molecules led to the discovery that Pak (p21-activated kinase)2 is a stress-responsive kinase localized in close proximity to the ER membrane in cardiomyocytes. We found that Pak2 cardiac deleted mice (Pak2-CKO) under tunicamycin stress or pressure overload manifested a defective ER response, cardiac dysfunction, and profound cell death. Small chemical chaperone tauroursodeoxycholic acid treatment of Pak2-CKO mice substantiated that Pak2 loss-induced cardiac damage is an ER-dependent pathology. Gene array analysis prompted a detailed mechanistic study, which revealed that Pak2 regulation of protective ER function was via the IRE (inositol-requiring enzyme)-1/XBP (X-box-binding protein)-1-dependent pathway. We further discovered that this regulation was conferred by Pak2 inhibition of PP2A (protein phosphatase 2A) activity. Moreover, IRE-1 activator, Quercetin, and adeno-associated virus serotype-9-delivered XBP-1s were able to relieve ER dysfunction in Pak2-CKO hearts. This provides functional evidence, which supports the mechanism underlying Pak2 regulation of IRE-1/XBP-1s signaling. Therapeutically, inducing Pak2 activation by genetic overexpression or adeno-associated virus serotype-9-based gene delivery was capable of strengthening ER function, improving cardiac performance, and diminishing apoptosis, thus protecting the heart from failure.

conclusionsOur findings uncover a new cardioprotective mechanism, which promotes a protective ER stress response via the modulation of Pak2. This novel therapeutic strategy may present as a promising option for treating cardiac disease and heart failure.

Indexed as

Endoplasmic Reticulum StressAnimalsApoptosisCell LineDisease Models, AnimalGenetic TherapyHeart FailureInduced Pluripotent Stem CellsMacaca mulattaMaleMembrane ProteinsMice, KnockoutMyocytes, Cardiacp21-Activated KinasesProtein Phosphatase 2Protein Serine-Threonine KinasesErn2 protein, mouseErn2 protein, ratMembrane Proteinsp21-Activated KinasesPAK2 protein, humanPak2 protein, mousePak2 protein, ratProtein Phosphatase 2Protein Serine-Threonine KinasesX-Box Binding Protein 1Xbp1 protein, mouseXbp1 protein, ratacidapoptosiscontrolendoplasmicheart failurequalityreticulumtauroursodeoxycholic

Identifiers

PMID30620686
PMCPMC6407830
OpenAlexW2911045660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.